IREN Increases Ordinary Share Offering to $6 Billion Under Sales Agreement

Tiger Newspress03-05 09:40

IREN announced Wednesday that it has expanded its ordinary share offering program, increasing the total amount available for sale to $6 billion under its At Market Issuance Sales Agreement. The company filed a new prospectus supplement, replacing its previous $1 billion offering from August 2025.

According to the SEC filing, Iren Limited has already sold 66,707,732 ordinary shares, raising an aggregate of $1 billion under the earlier prospectus supplement. With the new filing, the company may now offer and sell additional ordinary shares up to an aggregate offering price of $6 billion through or to a group of sales agents, including B. Riley Securities, Inc., Canaccord Genuity LLC, Cantor Fitzgerald & Co., Citigroup Global Markets Inc., Compass Point Research & Trading, LLC, J.P. Morgan Securities LLC, Macquarie Capital (USA) Inc., Roth Capital Partners LLC, Citizens JMP Securities, LLC, Goldman Sachs & Co. LLC, and Jefferies LLC.

The sales of ordinary shares will be conducted on the Nasdaq Stock Market LLC, and the amount sold at any time will be subject to the limits of the company’s registration statement and board authorization.

The ordinary shares are registered pursuant to Iren Limited’s shelf registration statement on Form S-3 (File No. 333-284369). The company noted that any offers or sales will be made only by means of a prospectus supplement.

The SEC filing also stated that Allens, counsel to Iren Limited, has issued a legal opinion regarding the ordinary shares, which was included as an exhibit to the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment